As a pioneer in the field of liver related elastography, FibroScan® is recognized worldwide as the non-invasive solution for a comprehensive management of liver health with more than 3,500 peer reviewed publications.
Our one-of-a-kind parameters
LSM by VCTE™ (Liver Stiffness Measurement by Vibration-Controlled Transient Elastography), CAP™ (controlled attenuation parameter) and SSM by VCTE™ (Spleen Stiffness Measurement) enable point of care, non-invasive diagnosis and monitoring.
LSM by VCTE™ is unique, patented and validated for Liver Stiffness Measurement.1
3,245 peer-reviewed publications support the use of LSM by VCTE™.
CAP™ is unique patented and validated for liver disease management.2,3
822 peer-reviewed publications support the use of CAP™.
SSM by VCTE™ is a unique, patented and validated new marker for Spleen Stiffness Measurement.4
109 peer-reviewed publications support the use of SSM by VCTE™.
3,500 peer-reviewed publications and more than 160 international guidelines evaluating, reporting or citing LSM by VCTE™ and CAP™.
VCTE™ can be used to accurately diagnose cirrhosis at an acceptable rate of false negatives and false positives in patients with chronic liver disease.
CAP™ is a point-of-care, standardized and reproducible technique, promising for the detection of liver steatosis.
TE is an established technique and is recommended as the initial assessment for significant liver fibrosis and cirrhosis (A1).
TE is a highly reproducible and user-friendly technique for assessing liver fibrosis in patients with chronic liver disease.
TE can be considered the non-invasive standard for the measurement of liver stiffness.
TE: Most widely used and validated technique for measurement of liver stiffness: standard to be beaten.
Vibration-controlled transient elastography (VCTE) is the most commonly used imaging-based fibrosis assessment method in the United States.
It has been validated in large cohorts worldwide in a spectrum of liver diseases, including hepatitis B, hepatitis C, fatty liver disease and autoimmune liver disorders, among others.
The Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) ambition is to revolutionize the ability to diagnose, monitor and treat metabolic liver disease by identifying non-invasive methods of diagnosing and assessing disease progression in non-alcoholic steatohepatitis (NASH). The partnership is spearheaded by the Foundation for National Institutes of Health (FNIH).
Echosens provides financial, clinical and material support, including the loan of FibroScan® devices, and the use of FibroScan-based composite biomarkers such as Fast™ and FibroMeter VCTE™ which combine circulating biomarkers with liver stiffness by vibration-controlled transient elastography as well as the FibroMeter™ which involves circulating biomarkers only.
1. European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
2. Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022.
3. Recio E, Cifuentes C, Macías J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool or the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911.doi:10.1097/MEG.0b013e32835f4c3d.
4. Stefanescu H, Marasco G, Calès P, et al. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-185. doi:10.1111/liv.14228.